Tigecycline is a drug owned by Amneal Pharmaceuticals Llc. It is protected by 2 US drug patents filed in 2018 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 07, 2033. Details of Tigecycline's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9855355 | Method and device for plasma-treating hollow bodies |
Apr, 2033
(7 years from now) | Active |
| US9855335 | Tigecycline composition for injection |
Apr, 2033
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tigecycline's patents.
Latest Legal Activities on Tigecycline's Patents
Given below is the list of recent legal activities going on the following patents of Tigecycline.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jul, 2024 | US8372995 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Aug, 2023 | US10588975 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jul, 2023 | US9254328 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Aug, 2022 | US8975242 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2022 | US7879828 (Litigated) |
| Expire Patent Critical | 07 Feb, 2022 | US9855355 |
| Maintenance Fee Reminder Mailed Critical | 23 Aug, 2021 | US9855355 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 07 Jul, 2021 | US9855335 |
| Surcharge for late Payment, Small Entity | 07 Jul, 2021 | US9855335 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 11 Jun, 2021 | US9855335 |
US patents provide insights into the exclusivity only within the United States, but Tigecycline is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tigecycline's family patents as well as insights into ongoing legal events on those patents.
Tigecycline's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tigecycline's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 07, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tigecycline Generic API suppliers:
Tigecycline is the generic name for the brand Tigecycline. 5 different companies have already filed for the generic of Tigecycline, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Tigecycline's generic
Alternative Brands for Tigecycline
There are several other brand drugs using the same active ingredient (Tigecycline) as Tigecycline. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Pf Prism Cv |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tigecycline, Tigecycline's active ingredient. Check the complete list of approved generic manufacturers for Tigecycline
About Tigecycline
Tigecycline is a drug owned by Amneal Pharmaceuticals Llc. Tigecycline uses Tigecycline as an active ingredient. Tigecycline was launched by Amneal in 2018.
Can you believe Tigecycline received compensation for the extended wait time during the regulatory approval process?
A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent. The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.
Approval Date:
Tigecycline was approved by FDA for market use on 02 August, 2018.
Active Ingredient:
Tigecycline uses Tigecycline as the active ingredient. Check out other Drugs and Companies using Tigecycline ingredient
Dosage:
Tigecycline is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50MG/VIAL | POWDER | Prescription | INTRAVENOUS |